Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374791 | 0.89 | KDM4E (0.45) | TRPM8RAB9ACYP1A2MEN1KMT2A | |
| SCHEMBL14875787 | 0.83 | P2RX7 (0.50) | P2RX7GRM5TRPM8RAB9ACYP1A2 | |
| SCHEMBL8575197 | 0.82 | P2RX7 (0.55) | P2RX7GRM5RAB9ACYP1A2MEN1 | |
| SCHEMBL4088056 | 0.81 | GRM5 (0.43) | GRM5TRPM8CYP1A2MEN1KMT2A | |
| SCHEMBL31546869 | 0.81 | CTSA (0.40) | TRPM8CYP1A2MEN1KMT2ACLK1 | |
| SCHEMBL307224 | 0.81 | GRM4 (0.46) | TRPM8RAB9ACYP1A2MEN1KMT2A | |
| SCHEMBL31546875 | 0.81 | CTSA (0.40) | TRPM8CYP1A2MEN1KMT2ACLK1 | |
| SCHEMBL306066 | 0.81 | ALDH1A1 (0.41) | TRPM8RAB9ACYP1A2MEN1KMT2A | |
| SCHEMBL14880117 | 0.81 | TRPM8 (0.39) | P2RX7TRPM8RAB9ACYP1A2MEN1 | |
| SCHEMBL5777696 | 0.80 | KDM4E (0.49) | GRM5RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4061809-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1601676-A2 | FUSED IMIDAZOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004078110-A2 | FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | P2RX7 49/4885GRM5 746/4885TRPM8 1305/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | P2RX7 514/4885GRM5 620/4885TRPM8 740/4885 |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | P2RX7 2892/4885GRM5 328/4885TRPM8 3182/4885 |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | P2RX7 618/4885GRM5 2325/4885TRPM8 235/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | P2RX7 589/4885GRM5 944/4885TRPM8 1527/4885 |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, SMAD2 | P2RX7 4550/4885GRM5 2742/4885TRPM8 3953/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | P2RX7 2892/4885GRM5 328/4885TRPM8 3182/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | P2RX7 2892/4885GRM5 328/4885TRPM8 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.